Effect of the H2 histamine receptor antagonist on oxygen metabolism in some morphotic blood elements in patients with ulcer disease.
OBJECTIVE
Our investigations was carried out in order to examine the effect of cimetidine, ranitidine and famotidine on the generation of free radicals, lipid peroxidation and enzymatic antioxidative defense in the blood of patients with peptic ulcer disease, clinically diagnosed as gastric or duodenal ulcer.


METHODS
124 non-smoking males (aged 20-51 years), were randomly divided into 4 groups: 28 patients received intravenously 200 mg of cimetidine; 26 patients intravenously 50 mg comprised of ranitidine; 25 patients received intravenously 20 mg of famotidine; and 45 healthy men served as the control group. Superoxide dismutase activity, malonyldialdehyde concentration in blood platelets and superoxide anion generation in granulocytes were determined in all examined men. An assay of superoxide dismutase activity and malonyldialdehyde concentration were performed before drug administration and after 2 and 72 hours. Superoxide anion generation was estimated before drug administration and after 2 hours.


RESULTS
Our data indicate that all examined H2 receptor antagonists stimulate superoxide dismutase activity, but after 72 hours a distinct increase was observed, in addition to a decrease of malonyldialdehyde concentration. No differences have been observed in superoxide anion generation in patients with ulcer disease or in healthy subjects before and after ranitidine and famotidine administration. Only after 2 hours of cimetidine administration was a significant increase in superoxide anion generation observed.


CONCLUSIONS
We concluded that H2 receptor antagonists have a beneficial effect on antioxidative processes.
Kedziora-Kornatowska
K
K
Department of Gastroenterology, Military Medical University, Lodz, Poland.
Tkaczewski
W
W
Blaszczyk
J
J
Buczynski
A
A
Chojnacki
J
J
Kedziora
J
J
D000328:Adult; D001792:Blood Platelets / Q000378:metabolism; D002927:Cimetidine / Q000008:administration & dosage / Q000494:pharmacology; D015738:Famotidine / Q000008:administration & dosage / Q000494:pharmacology; D005609:Free Radicals / Q000097:blood; D006098:Granulocytes / Q000378:metabolism; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D007275:Injections, Intravenous; D015227:Lipid Peroxidation; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008875:Middle Aged; D010437:Peptic Ulcer / Q000097:blood* / Q000188:drug therapy; D011899:Ranitidine / Q000008:administration & dosage / Q000494:pharmacology; D013482:Superoxide Dismutase / Q000097:blood*; D013481:Superoxides / Q000097:blood*
D005609:Free Radicals; D006635:Histamine H2 Antagonists; D013481:Superoxides; D008315:Malondialdehyde; D015738:Famotidine; D002927:Cimetidine; D011899:Ranitidine; D013482:Superoxide Dismutase